Name (Synonyms) | Correlation | |
---|---|---|
drug1273 | Ivermectin + Doxycycline + Placebo Wiki | 1.00 |
drug1274 | Ivermectin + Placebo Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this trial is to conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an antiviral and immunomodulator in asymptomatic subjects with recent exposure to a person with severe acute respiratory syndrome (SARS) or possible SARS. The primary objective of this pilot study is to determine an Alferon LDO dose level that increases or upregulates genes known to be mediators of interferon response. Secondary endpoints include the development of SARS symptomatology, rate of hospitalization, and mortality rate. In the event that no subjects with recent exposure to a person with SARS or possible SARS are available, this study will be conducted with 10 normal volunteers.
Description: Increased expression of genes known to be mediators of interferon response.
Measure: Gene expression analysis Time: Days 0, 2, 6, 11, 12, 15, 20 and 40Description: Development of clinical SARS-CoV symptomatology
Measure: SARS CoV Antibody Time: Days 0, 15, 20 and 40Description: Hospitalization for SARS-CoV infection and Death
Measure: SARS-CoV infection